EFFECT OF SEMAGLUTIDE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS AND ITS APPLICABILITY IN THE CONTEXT OF PRIMARY CARE: A LITERATURE REVIEW.

• Autor(a) principal: Sad , Elis Pinheiro
• Data de Publicação: 2024
• Outros Autores: Landim, Maria Teresa de Oliveira Paes, Santos , Luiz Felipe Duarte Dos, Arlota , Fernanda Bortoli, Melo , Igor Barreto, Pires , Vivian Saeger, Dias, Rogério Belício, Simon, Mariana Saloum, Almeida, Rayana Hellen Gamosa, Fontana , Isabela Meneses de Morais, Silva , Paloma Encinas Beramendi, Paulino , Luciano Pinto, Franco, Natália Almeida Pinheiro, Brito , Ogi Janderson Antunes de Castro, Dias , Mariana Oliveira, Pinho, Victoria Alves, Badini , Rômulo Rodrigues, Nascimento , Alexandre Augusto de Sousa
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Brazilian Journal of Implantology and Health Sciences
• Texto Completo: https://bjihs.emnuvens.com.br/bjihs/article/view/1604
• topic: agonista do receptor GLP-1; antidiabéticos; atenção básica; custo-efetividade; Diabetes Mellitus tipo 2; Semaglutida.; GLP-1 receptor agonist; antidiabetics; basic care; cost-effectiveness; Type 2 Diabetes Mellitus; Semaglutide.

Type 2 Diabetes Mellitus (DM2) is a disease characterized by a set of metabolic disorders that result in altered glycemic levels and, in the medium and long term, the appearance of lesions in target organs when not treated appropriately. This condition can be controlled by diet, physical exercise and drugs indicated for its treatment, and should always be monitored by a trained professional and, ideally, a multidisciplinary team. The purpose of this study was to address a generalized view of DM2 in relation to its pathophysiology, etiology and prognosis. Point out the possible medications for your treatment and their respective mechanisms of action, establishing a cost-effective relationship so that care occurs in the most favorable way possible. Furthermore, deepen knowledge about the use of Semaglutide in the treatment of people with DM2 related to its applicability in the context of primary care, evaluating its effectiveness, incidence of adverse reactions, economic viability and comparing it with other hypoglycemic agents available in the SUS. To construct this study, a bibliographical review of articles related to the topic was carried out, reaching the conclusion that shared therapy between doctor and patient combined with individualized treatment is necessary. The use of Semaglutide proved to be beneficial in terms of glycemic control and weight loss, however, attention should be paid to its adverse effects, mainly related to the gastrointestinal system.